- Home
- BRW vs CRMD Comparison
BRW vs CRMD Comparison
Compare BRW & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRW | CRMD |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.5M | 590.7M |
| IPO Year | 1996 | 2009 |
Fundamental Metrics
Financial Performance| Metric | BRW | CRMD |
|---|---|---|
| Price | $6.52 | $8.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.83 |
| AVG Volume (30 Days) | 220.2K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.71 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $6.38 | $6.13 |
| 52 Week High | $8.19 | $13.48 |
Technical Indicators
Market Signals| Indicator | BRW | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 50.98 |
| Support Level | $6.41 | $8.08 |
| Resistance Level | $6.58 | $9.01 |
| Average True Range (ATR) | 0.07 | 0.29 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 62.50 | 21.90 |
Price Performance
Historical ComparisonAbout BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.